vs
Side-by-side financial comparison of CB Financial Services, Inc. (CBFV) and Sanara MedTech Inc. (SMTI). Click either name above to swap in a different company.
Sanara MedTech Inc. is the larger business by last-quarter revenue ($27.5M vs $13.8M, roughly 2.0× CB Financial Services, Inc.). On growth, CB Financial Services, Inc. posted the faster year-over-year revenue change (19.9% vs 4.6%). CB Financial Services, Inc. produced more free cash flow last quarter ($17.2M vs $3.9M). Over the past eight quarters, Sanara MedTech Inc.'s revenue compounded faster (21.8% CAGR vs 1.2%).
CB Bank is one of Myanmar's largest commercial banks. It became the first bank in Myanmar to issue ATM cards and credit cards. The bank, led by U Khin Maung Aye (Chairman) and U Kyaw Thu Ko (CEO) has over 245 branches across the country.
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
CBFV vs SMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $27.5M |
| Net Profit | — | $-1.6M |
| Gross Margin | — | 93.2% |
| Operating Margin | 38.1% | 23.5% |
| Net Margin | — | -5.9% |
| Revenue YoY | 19.9% | 4.6% |
| Net Profit YoY | — | 5.3% |
| EPS (diluted) | $0.90 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $27.5M | ||
| Q3 25 | $2.4M | $26.3M | ||
| Q2 25 | $13.5M | $25.8M | ||
| Q1 25 | $12.1M | $23.4M | ||
| Q4 24 | $13.2M | $26.3M | ||
| Q3 24 | $12.7M | $21.7M | ||
| Q2 24 | $12.2M | $20.2M | ||
| Q1 24 | $13.5M | $18.5M |
| Q4 25 | — | $-1.6M | ||
| Q3 25 | $-5.7M | $-30.4M | ||
| Q2 25 | $3.9M | $-2.0M | ||
| Q1 25 | $1.9M | $-3.5M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | $3.2M | $-2.9M | ||
| Q2 24 | $2.6M | $-3.5M | ||
| Q1 24 | $4.2M | $-1.8M |
| Q4 25 | — | 93.2% | ||
| Q3 25 | — | 92.9% | ||
| Q2 25 | — | 92.5% | ||
| Q1 25 | — | 92.2% | ||
| Q4 24 | — | 91.4% | ||
| Q3 24 | — | 90.8% | ||
| Q2 24 | — | 90.0% | ||
| Q1 24 | — | 89.8% |
| Q4 25 | 38.1% | 23.5% | ||
| Q3 25 | -289.8% | 11.2% | ||
| Q2 25 | 35.0% | -0.1% | ||
| Q1 25 | 19.3% | -8.9% | ||
| Q4 24 | 23.1% | 18.6% | ||
| Q3 24 | 31.2% | 3.6% | ||
| Q2 24 | 26.4% | -14.3% | ||
| Q1 24 | 37.9% | -8.3% |
| Q4 25 | — | -5.9% | ||
| Q3 25 | -235.2% | -115.5% | ||
| Q2 25 | 29.3% | -7.8% | ||
| Q1 25 | 15.8% | -15.1% | ||
| Q4 24 | — | -6.5% | ||
| Q3 24 | 25.3% | -13.2% | ||
| Q2 24 | 21.8% | -17.4% | ||
| Q1 24 | 31.1% | -9.5% |
| Q4 25 | $0.90 | $-0.32 | ||
| Q3 25 | $-1.07 | $-3.40 | ||
| Q2 25 | $0.74 | $-0.23 | ||
| Q1 25 | $0.35 | $-0.41 | ||
| Q4 24 | $0.45 | $-0.18 | ||
| Q3 24 | $0.60 | $-0.34 | ||
| Q2 24 | $0.51 | $-0.41 | ||
| Q1 24 | $0.82 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.7M | $16.6M |
| Total DebtLower is stronger | — | $46.0M |
| Stockholders' EquityBook value | $157.5M | $5.9M |
| Total Assets | $1.5B | $72.9M |
| Debt / EquityLower = less leverage | — | 7.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.7M | $16.6M | ||
| Q3 25 | $55.9M | $14.9M | ||
| Q2 25 | $64.5M | $17.0M | ||
| Q1 25 | $61.3M | $20.7M | ||
| Q4 24 | $49.6M | $15.9M | ||
| Q3 24 | $147.3M | $16.3M | ||
| Q2 24 | $142.6M | $6.2M | ||
| Q1 24 | $73.7M | $2.8M |
| Q4 25 | — | $46.0M | ||
| Q3 25 | — | $45.1M | ||
| Q2 25 | — | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $9.7M |
| Q4 25 | $157.5M | $5.9M | ||
| Q3 25 | $152.5M | $6.1M | ||
| Q2 25 | $148.4M | $35.4M | ||
| Q1 25 | $148.3M | $36.7M | ||
| Q4 24 | $147.4M | $39.4M | ||
| Q3 24 | $149.1M | $39.8M | ||
| Q2 24 | $142.9M | $41.7M | ||
| Q1 24 | $141.6M | $43.3M |
| Q4 25 | $1.5B | $72.9M | ||
| Q3 25 | $1.5B | $71.1M | ||
| Q2 25 | $1.5B | $98.8M | ||
| Q1 25 | $1.5B | $96.4M | ||
| Q4 24 | $1.5B | $88.1M | ||
| Q3 24 | $1.6B | $88.5M | ||
| Q2 24 | $1.6B | $73.4M | ||
| Q1 24 | $1.5B | $70.9M |
| Q4 25 | — | 7.74× | ||
| Q3 25 | — | 7.33× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.8M | $3.9M |
| Free Cash FlowOCF − Capex | $17.2M | $3.9M |
| FCF MarginFCF / Revenue | 124.1% | 14.0% |
| Capex IntensityCapex / Revenue | 4.7% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $29.5M | $2.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.8M | $3.9M | ||
| Q3 25 | $4.6M | $2.2M | ||
| Q2 25 | $4.1M | $2.7M | ||
| Q1 25 | $4.0M | $-2.0M | ||
| Q4 24 | $6.8M | $932.0K | ||
| Q3 24 | $3.1M | $2.1M | ||
| Q2 24 | $-1.2M | $-1.4M | ||
| Q1 24 | $3.3M | $-1.6M |
| Q4 25 | $17.2M | $3.9M | ||
| Q3 25 | $4.5M | $1.1M | ||
| Q2 25 | $3.9M | $902.7K | ||
| Q1 25 | $3.9M | $-3.7M | ||
| Q4 24 | $3.4M | $859.9K | ||
| Q3 24 | $2.2M | $2.0M | ||
| Q2 24 | $-2.4M | $-1.5M | ||
| Q1 24 | $2.3M | $-1.7M |
| Q4 25 | 124.1% | 14.0% | ||
| Q3 25 | 186.5% | 4.2% | ||
| Q2 25 | 28.8% | 3.5% | ||
| Q1 25 | 32.5% | -15.9% | ||
| Q4 24 | 26.0% | 3.3% | ||
| Q3 24 | 17.4% | 9.4% | ||
| Q2 24 | -19.6% | -7.3% | ||
| Q1 24 | 17.0% | -9.0% |
| Q4 25 | 4.7% | 0.3% | ||
| Q3 25 | 4.3% | 4.0% | ||
| Q2 25 | 1.9% | 6.8% | ||
| Q1 25 | 0.8% | 7.4% | ||
| Q4 24 | 25.1% | 0.3% | ||
| Q3 24 | 6.7% | 0.0% | ||
| Q2 24 | 10.0% | 0.3% | ||
| Q1 24 | 7.2% | 0.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 2.11× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.95× | — | ||
| Q2 24 | -0.44× | — | ||
| Q1 24 | 0.78× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBFV
Segment breakdown not available.
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
